Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Healthcare Shares
Why is the Cochlear share price slipping on Wednesday?
Dividend Investing
Here's how to grab your piece of the latest Cochlear dividend
Dividend Investing
Here are 3 ASX 200 shares turning ex-dividend tomorrow
Healthcare Shares
ASX 200 better buy: Cochlear or CSL shares?
Broker Notes
Goldman Sachs says these ASX shares are flying under the radar post-results
Healthcare Shares
How do CSL shares stack up against Cochlear following earnings season?
Blue Chip Shares
Here's why analysts say these blue chip ASX 200 shares are buys
Blue Chip Shares
3 buy-rated ASX 200 shares that analysts love
Broker Notes
Goldman Sachs tips Cochlear share price to rise 13%
Share Market News
5 things to watch on the ASX 200 on Monday
Share Gainers
Why Accent, Cochlear, Newcrest, and Santos shares are charging higher today
Healthcare Shares
Cochlear share price takes off despite guidance miss
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
